Literature DB >> 2991614

A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra.

Y Kunisawa, K Kawabe, T Niijima, K Honda, T Takenaka.   

Abstract

Postsynaptic alpha adrenergic receptor subtypes mediating contraction of human urinary bladder base and prostatic urethra were investigated in vitro. Alpha adrenergic receptor agonists, noradrenaline and phenylephrine, induced contraction dose-dependently in these tissues. Alpha adrenergic receptor antagonists, prazosin and yohimbine, competitively antagonized the contraction induced by these agonists in the bladder base as well as prostatic urethra. The mean pA2 values for the antagonists in the bladder base and prostatic urethra were as follows: 8.89 and 8.96 for prazosin and 6.30 and 6.45 for yohimbine, respectively. Comparison of pA2 values of prazosin and yohimbine in both the tissues with those values found in the literature for these compounds in a variety of tissues containing alpha-1 or alpha-2 adrenergic receptor indicates that the postsynaptic alpha adrenergic receptor subtype in the human urinary bladder base and prostatic urethra is the alpha-1 type, not the alpha-2 type.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991614     DOI: 10.1016/s0022-5347(17)47185-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

1.  Receptor function studies in specimens from the proximal human urethra obtained by transurethral resection.

Authors:  P Amark; A C Kinn; A Nergårdh
Journal:  Urol Res       Date:  1992

2.  Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans.

Authors:  K Harada; M Ohmori; A Fujimura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

3.  alpha 1-Adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits.

Authors:  K Honda; A Miyata-Osawa; T Takenaka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

Review 4.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 5.  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; D McTavish
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

6.  Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract.

Authors:  F Lefèvre-Borg; S E O'Connor; H Schoemaker; P E Hicks; J Lechaire; E Gautier; F Pierre; C Pimoule; P Manoury; S Z Langer
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

Review 7.  Chronic pelvic pain syndrome and voiding dysfunction.

Authors:  Werner W Hochreiter; Sebastian Z'Brun
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 3.092

8.  The presence and distribution of alpha adrenergic receptors in human renal pelvis and calyces.

Authors:  Osman Raif Karabacak; Demet Yilmazer; Ufuk Ozturk; Nevzat Can Sener; Hakan Saltas; Yurdum Karabacak; Murat Alper
Journal:  Urolithiasis       Date:  2013-07-23       Impact factor: 3.436

9.  Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery.

Authors:  A Hatano; H Takahashi; M Tamaki; T Komeyama; T Koizumi; M Takeda
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

10.  A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.

Authors:  Miguel Maldonado-Ávila; Hugo A Manzanilla-García; José A Sierra-Ramírez; José D Carrillo-Ruiz; Juan C González-Valle; Emanuelle Rosas-Nava; José Guzman-Esquivel; Isaac R Labra-Salgado
Journal:  Int Urol Nephrol       Date:  2013-09-24       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.